Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL6323725 | 0.81 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL23152606 | 0.78 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL27568072 | 0.78 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL575705 | 0.78 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL7006307 | 0.78 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL5187479 | 0.78 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL27713140 | 0.76 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL30505750 | 0.76 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL8817892 | 0.76 | CA1 (0.40) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL7320428 | 0.75 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282806-A1 | CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN | JIANGNAN UNIVERSITY (CN) | 2025-09-11 | — | — | US | claimed |
| CN-115232177-A | Chemical synthesis method of shigella dysenteriae type 10O-antigen oligosaccharide | 江南大学 | 2022-10-25 | — | — | CN | claimed |
| US-20250282806-A1 | CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN | JIANGNAN UNIVERSITY (CN) | 2025-09-11 | — | — | US | disclosed |
| CN-115232177-A | Chemical synthesis method of shigella dysenteriae type 10O-antigen oligosaccharide | 江南大学 | 2022-10-25 | — | — | CN | disclosed |
| EP-2415775-B1 | AGENT FOR INHIBITING THICKENING OF PERITONEAL MEMBRANE | CCI CORP (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-8841262-B2 | Agent for inhibiting peritoneal membrane thickening | CCI CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8524873-B2 | Sugar donor | RIKEN (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120083461-A1 | AGENT FOR INHIBITING PERITONEAL MEMBRANE THICKENING | CCI CORPORATION (JP) | 2012-04-05 | — | — | US | disclosed |
| EP-2415775-A1 | AGENT FOR INHIBITING THICKENING OF PERITONEAL MEMBRANE | CCI CORPORATION (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110286937-A1 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME | GIFU UNIVERSITY (JP) | 2011-11-24 | — | — | US | disclosed |
| US-8003615-B2 | Stable vitamin B6 derivative | DAIICHI FINE CHEMICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| EP-0953357-A1 | NEPHROTROPIC DRUGS | Drug Delivery System Institute, Ltd. (JP) | 1999-11-03 | — | — | EP | disclosed |
| US-5808018-A | Fluorine containing sialyl Lewis X derivatives and synthetic intermediates thereof | DAIKIN INDUSTRIES, LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0811634-A1 | FLUORINATED SIALYL-LEWIS X DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF | DAIKIN INDUSTRIES, LIMITED (JP) | 1997-12-10 | — | — | EP | disclosed |
| US-5686426-A | Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| US-5627270-A | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same | TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0719787-A1 | Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0688329-A1 | NOVEL PHOSPHOLIPID-SACCHARIDE CONJUGATES | GENZYME CORPORATION (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994021656-A2 | NOVEL PHOSPHOLIPID-SACCHARIDE CONJUGATES | GENZYME CORPORATION (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1993011772-A1 | GLYCOSYLATED STEROID DERIVATIVES FOR TRANSPORT ACROSS BIOLOGICAL MEMBRANES AND PROCESS FOR MAKING SAME | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110286937-A1 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME | UGCG, SGMS2, CERT1 | ALDH1A1 4476/4885L3MBTL1 1038/4885 |
| US-20250282806-A1 | CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN | OGA, DDOST, FUT6 | ALDH1A1 3415/4885L3MBTL1 1874/4885 |
| US-20120083461-A1 | AGENT FOR INHIBITING PERITONEAL MEMBRANE THICKENING | ASGR1, MGAT1, SI | ALDH1A1 4043/4885L3MBTL1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.